Could a gallium pill reach brain tumors? tiny trial aims to find out
NCT ID NCT07515924
First seen Apr 11, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This early-stage trial will test whether an oral drug called gallium maltolate can reach brain tumors in people with recurrent glioblastoma. Eight participants will take the drug for about two weeks before surgery, and researchers will measure gallium levels in the removed tumor tissue. The goal is not to treat the cancer but to see if the drug penetrates the brain, which could guide future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gallium maltolate
What this could lead to
If successful, this could show that gallium maltolate reaches brain tumors, pointing toward a potential new treatment for glioblastoma.
What could go wrong
This is a very early Phase 0 trial with only 8 participants. It is designed to measure drug levels, not to test effectiveness or safety. The drug may not reach therapeutic concentrations or may cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.